How is MKC-1106-PP Different?

Our approach is to identify the non-tolerated epitopes on the cancer cell surface, and our plasmid and peptide analogs are designed to activate an immune response, which may lead to the destruction of the cancer by the immune system.

In contrast to the conventional subcutaneous or intramuscular route of administration, our compounds are delivered directly into the patient’s lymph nodes, sites rich in T-cells and APC. This delivery method ensures that T-cells will be exposed to greater concentrations of antigen for a longer period of time than that occurring after immunization by other routes.